Raúl Romero-Sevilla, Fidel López-Espuela, José Manuel Fuentes, Beatriz Duque de San Juan, Juan Carlos Portilla-Cuenca, Carmen Cámara Hijon and Ignacio Casado-Naranjo Pages 68 - 75 ( 8 )
Background: The effect that cytokines can exert on the progression from mild cognitive impairment (MCI) to ongoing dementia is a matter of debate and the results obtained so far are controversial. <p> Objective: The aim of the study is to analyze the influence of markers of subclinical inflammation on the progression of MCI to dementia. <p> Methods: A prospective study involving a cohort of patients ≥ 65 years of age diagnosed with MCI and followed for 3 years was conducted. 105 patients were enrolled, and serum concentrations of several subclinical inflammatory markers were determined. <p> Results: After 3.09 (2 - 3.79) years of follow-up, 47 (44.76%) patients progressed to dementia. Alpha 1-antichymotrypsin (ACT) was found to be significantly higher in patients who progressed to dementia (486.45 ± 169.18 <i>vs</i>. 400.91 ± 163.03; <i>p</i> = 0.012), and observed to significantly increase the risk of developing dementia in patients with mild cognitive impairment (1.004, 1.001-1.007; <i>p</i> = 0.007). IL-10 levels were significantly higher in those who remained stable (6.69 ± 18.1 <i>vs</i>. 32.54 ± 89.6; <i>p</i> = 0.04). Regarding the type of dementia to which our patients progressed, we found that patients who developed mixed dementia had higher IL-4 levels than those who converted to AD (31.54 ± 63.6 vs. 4.43 ± 12.9; <i>p</i> = 0.03). No significant differences were observed between the groups with regard to the ESR and LPa, CRP, IL-1 and TNF-α levels. <p> Conclusion: ACT levels have a significant predictive value in the conversion of MCI to dementia. IL-10 levels could be a protective factor. It is necessary to conduct studies with serial determinations of these and other inflammatory markers in order to determine their effect on the progression of MCI to dementia.
Alpha 1-antichymotrypsin, anti-inflammatory cytokines IL-10, cytokines, dementia, inflammation, mild cognitive impairment, subclinical inflammation.